Kiniksa Pharmaceuticals International, plc (KNSA) — SEC Filings

Latest SEC filings for Kiniksa Pharmaceuticals International, plc (KNSA), explained in plain English.

Sentiment Overview: 3 bullish, 2 bearish, 41 neutral

Recent Filings (46)

• Kiniksa Pharmaceuticals Files Form 144 for Security Sale — 144 · 2026-04-09T16:02:53-04:00 [neutral] Risk: medium
  On April 9, 2026, Kiniksa Pharmaceuticals International, plc filed a Form 144, indicating a proposed sale of securities. The filing was made by Michael R. Megna
• 4 Filing — 4 · 2026-04-08T16:43:07-04:00 [neutral]
• Kiniksa Pharmaceuticals Files Form 4 on April 8, 2026 — 4 · 2026-04-08T16:34:47-04:00 [neutral] Risk: low
  On April 8, 2026, Kiniksa Pharmaceuticals International, plc filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transact
• Kiniksa Swings to Profit on 61% ARCALYST Revenue Jump — 10-Q · 2025-10-28T00:00:00.000Z [bullish] Risk: medium
  Kiniksa Pharmaceuticals International, plc reported a significant financial turnaround for the three and nine months ended September 30, 2025. Product revenue,
• Kiniksa Pharmaceuticals 8-K Filing — 8-K · 2025-09-03T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc reported on September 3, 2025, that its Class A Ordinary Shares trade under the symbol KNSA on the Nasdaq Global Sele
• Kiniksa Pharmaceuticals Files 8-K on Operations — 8-K · 2025-07-29T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on July 29, 2025, reporting on its results of operations and financial condition, as well as financial s
• Kiniksa's Q2 Net Loss Widens to $43.4M Amid Rising Expenses — 10-Q · 2025-07-29T00:00:00.000Z [bearish] Risk: high
  Kiniksa Pharmaceuticals International, plc reported a net loss of $43.4 million for the three months ended June 30, 2025, a significant increase from the $37.6
• Kiniksa Pharmaceuticals Files 8-K — 8-K · 2025-06-05T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on June 5, 2025, reporting information under Regulation FD and including financial statements and exhibi
• Kiniksa Pharmaceuticals 8-K Filing on Shareholder Votes — 8-K · 2025-06-03T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on June 3, 2025, to report on matters submitted to a vote of its security holders. The filing details th
• Kiniksa Pharma Files 2025 Proxy Statement — DEFA14A · 2025-05-28T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed a Definitive Proxy Statement (DEFA14A) on May 28, 2025, for its 2025 Annual Meeting of Shareholders. The filing
• Kiniksa Pharma Files Proxy Materials — DEFA14A · 2025-05-09T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed a Definitive Additional Materials proxy statement on May 9, 2025. This filing relates to the company's proxy ma
• Kiniksa Pharmaceuticals Files 8-K on Financials — 8-K · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on April 29, 2025, reporting on its results of operations and financial condition. The filing also inclu
• Kiniksa Pharmaceuticals Q1 2025 Update — 10-Q · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates
• Kiniksa Pharma Reports Director/Officer Changes & Compensatory Info — 8-K · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on April 23, 2025, reporting events as of April 17, 2025. The filing pertains to the departure of direct
• Kiniksa Pharma Files 2025 Proxy Statement — DEF 14A · 2025-04-21T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed its definitive proxy statement (DEF 14A) on April 21, 2025, for its annual meeting on June 3, 2025. The filing
• Kiniksa Pharmaceuticals Terminates Material Agreement — 8-K · 2025-02-25T00:00:00.000Z [neutral] Risk: medium
  On February 21, 2025, Kiniksa Pharmaceuticals International, plc filed an 8-K reporting the termination of a material definitive agreement. The filing also cove
• Kiniksa Pharmaceuticals: $35.8M Assets vs $41.9M Liabilities in 2024 — 10-K · 2025-02-25T00:00:00.000Z [bearish] Risk: medium
  Kiniksa Pharmaceuticals International, plc filed its 2024 10-K on February 25, 2025, reporting its financial performance for the fiscal year ending December 31,
• Kiniksa Pharmaceuticals Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-13T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• Kiniksa Pharmaceuticals Files 8-K on Operations — 8-K · 2024-10-29T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed an 8-K on October 29, 2024, to report on its results of operations and financial condition, and to file financi
• Kiniksa Pharma Files Q3 2024 10-Q — 10-Q · 2024-10-29T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals International, plc filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position, includi
• SC 13G Filing — SC 13G · 2024-10-21T00:00:00.000Z [neutral]
• Baker Bros. Advisors Updates Kiniksa Pharma Stake — SC 13D/A · 2024-10-08T00:00:00.000Z [neutral] Risk: medium
  Baker Bros. Advisors LP, through its affiliates FBB3 LLC and Baker Bros. Advisors (GP) LLC, has amended its Schedule 13D filing regarding Kiniksa Pharmaceutical
• Kiniksa Appoints New CEO, Dr. Sanj K. Patel — 8-K · 2024-10-07T00:00:00.000Z [neutral] Risk: medium
  Kiniksa Pharmaceuticals International, plc announced on October 7, 2024, that Dr. Sanj K. Patel will be appointed as Chief Executive Officer and a member of the
• Kiniksa Pharmaceuticals Q2 2024 Update — 10-Q · 2024-07-25T00:00:00.000Z [neutral] Risk: medium
  Kiniksa Pharmaceuticals International, plc filed its 10-Q for the period ending June 30, 2024. The company reported significant financial figures, including $16
• Kiniksa Pharmaceuticals Files 8-K on Operations — 8-K · 2024-07-23T00:00:00.000Z [neutral] Risk: low
  On July 23, 2024, Kiniksa Pharmaceuticals International, plc filed an 8-K report. The filing primarily concerns the company's results of operations and financia
• Kiniksa Pharmaceuticals Enters Material Definitive Agreement — 8-K · 2024-06-25T00:00:00.000Z [neutral] Risk: medium
  Kiniksa Pharmaceuticals, Ltd. announced on June 25, 2024, that it has entered into a material definitive agreement. The company, incorporated in Bermuda with it
• Kiniksa Pharmaceuticals Files 8-K Report — 8-K · 2024-06-14T00:00:00.000Z [neutral] Risk: low
  On June 14, 2024, Kiniksa Pharmaceuticals, Ltd. filed an 8-K report. The filing indicates that the company is incorporated in Bermuda and provides its principal
• Kiniksa Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · 2024-06-05T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals, Ltd. filed an 8-K on June 5, 2024, to report on the submission of matters to a vote of security holders. The filing does not contain sp
• Kiniksa Pharma Files Proxy Statement for Shareholder Meeting — DEFA14A · 2024-05-29T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals, Ltd. filed a Definitive Proxy Statement (DEFA14A) on May 29, 2024, related to a Special Court-Ordered Meeting of Shareholders. The fili
• Kiniksa Pharmaceuticals, Ltd. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals, Ltd. (KNSA) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Kiniksa Pharmaceuticals, Ltd. filed a 10-Q report for the p
• Kiniksa Pharmaceuticals Schedules 2024 Annual Meeting and Special Redomiciliation Meeting — DEF 14A · 2024-04-23T00:00:00.000Z [neutral] Risk:
  Kiniksa Pharmaceuticals, Ltd. (KNSA) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Kiniksa Pharmaceuticals, Ltd. will hold its 2024 Annual M
• SC 13G/A Filing — SC 13G/A · 2024-04-05T00:00:00.000Z [neutral]
• Kiniksa Pharmaceuticals Files 8-K — 8-K · 2024-04-02T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals, Ltd. filed an 8-K on April 2, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Kiniksa Pharmaceuticals Files 8-K — 8-K · 2024-03-29T00:00:00.000Z [neutral] Risk: low
  On March 29, 2024, Kiniksa Pharmaceuticals, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
• Kiniksa Pharmaceuticals Files 8-K on Financial Condition — 8-K · 2024-02-28T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals, Ltd. filed an 8-K on February 28, 2024, regarding its results of operations and financial condition. This filing indicates the company
• Kiniksa Pharmaceuticals, Ltd. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-28T00:00:00.000Z [neutral] Risk: low
  Kiniksa Pharmaceuticals, Ltd. (KNSA) filed a Annual Report (10-K) with the SEC on February 28, 2024. Kiniksa Pharmaceuticals, Ltd. reported total assets of $1,7
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Rubric Capital Discloses 2.9M Share Stake in Kiniksa Pharma — SC 13G · 2024-02-12T00:00:00.000Z [bullish] Risk: low
  Rubric Capital Management LP, a Delaware-based investment firm, reported beneficial ownership of 2,907,501 Class A Common Shares of Kiniksa Pharmaceuticals, Ltd
• BlackRock Discloses Significant Stake in Kiniksa Pharma — SC 13G · 2024-01-25T00:00:00.000Z [bullish]
  BlackRock, Inc., a major investment firm, reported its ownership in Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) as of December 31, 2023. This SC 13G filing ind
• Kiniksa Pharma Files 8-K on Operations & Financial Condition — 8-K · 2024-01-04T00:00:00.000Z [neutral]
  Kiniksa Pharmaceuticals, Ltd. filed an 8-K on January 4, 2024, to report on its results of operations and financial condition, as well as to make a Regulation F